Skip to main content

Table 2 Patients who stopped tolvaptan treatment due to improved ascites

From: Impact of continued administration of tolvaptan on cirrhotic patients with ascites

Age (years old) Sex Etiology of liver disease Tolvaptan treatment (days) Requirement for restarting of tolvaptan Furosemide (mg/day) Spironolactone (mg/day) Modified CP score Event
60s Male Alcoholic liver disease 126   80 400 11 Discontinued drinking
40s Male Hepatitis C virus-related liver disease+ alcoholic liver disease 1226 Yes 20 25 13 Discontinued drinking
40s Male Alcoholic liver disease 49 Yes 20 100 12 Discontinued drinking
70s Male Primary sclerosing cholangitis 335   160 100 11 Decreased protein urea
60s Male Hepatitis B virus-related liver disease 249 Yes 20 25 10 Treatment with nucleic acid analog
80s Female Hepatitis C virus-related liver disease 187   20 50 8 Disappearance of portal vein thrombosis
70s Male Alcoholic liver disease 293   20 25 10 Discontinued drinking
60s Male Alcoholic liver disease+MTX associated liver disease 186   10 25 11 Discontinued MTX
60s Female Alcoholic liver disease 139   10 25 12 Discontinued drinking
  1. CP Child-Pugh, MTX methotrexate